{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:25:18Z","timestamp":1790079918967,"version":"4.0.1"},"reference-count":61,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2015,4,13]],"date-time":"2015-04-13T00:00:00Z","timestamp":1428883200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Centro Ricerca e Cura delle Malattie Infiammatorie Croniche Intestinali, IRCCS Istituto Clinico Humanitas"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Budesonide and mesalazine (mesalamine) are commonly used in the medical management of patients with mild to moderate Crohn's disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To assess their comparative efficacy and harm using the methodology of network meta\u2010analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A comprehensive search of Medline, Embase, the Cochrane Library and <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>, through October 2014, was performed to identify randomised controlled trials (<jats:styled-content style=\"fixed-case\">RCT<\/jats:styled-content>s) that recruited adult patients with active or quiescent Crohn's disease, and compared budesonide or mesalazine with placebo, or against each other, or different dosing strategies of one drug.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty\u2010five <jats:styled-content style=\"fixed-case\">RCT<\/jats:styled-content>s were combined using Bayesian network meta\u2010analysis. Budesonide 9\u00a0mg\/day, or at higher doses (15 or 18\u00a0mg\/day), was shown superior to placebo for induction of remission [odds ratio (<jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content>), 2.93; 95% credible interval (CrI), 1.52\u20135.39, and <jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content>, 3.28; CrI, 1.46\u20137.55 respectively] and ranks at the top of the hierarchy of the competing treatments. For maintenance of remission, budesonide 6\u00a0mg\/day demonstrated superiority over placebo (<jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content>, 1.69; CrI, 1.05\u20132.75), being also at the best ranking position among all compared treatment strategies. No other comparisons (i.e. different doses of mesalazine vs. placebo or budesonide, for induction or maintenance of remission) reached significance. The occurrence of withdrawals due to adverse events was not shown different between budesonide, mesalazine and placebo, in both the induction and maintenance phases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Budesonide, at the doses of 9\u00a0mg\/day, or higher, for induction of remission in active mild or moderate Crohn's disease, and at 6\u00a0mg\/day for maintenance of remission, appears to be the best treatment choice.<\/jats:p><\/jats:sec>","DOI":"10.1111\/apt.13190","type":"journal-article","created":{"date-parts":[[2015,4,13]],"date-time":"2015-04-13T06:23:02Z","timestamp":1428906182000},"page":"1055-1065","source":"Crossref","is-referenced-by-count":70,"title":["Systematic review with network meta\u2010analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease"],"prefix":"10.1111","volume":"41","author":[{"given":"L.","family":"Moja","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences for Health University of Milan Milan Italy"},{"name":"Unit of Clinical Epidemiology IRCCS Galeazzi Orthopedic Institute Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Danese","sequence":"additional","affiliation":[{"name":"IBD Center Department of Gastroenterology IRCCS Humanitas Research Hospital Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Fiorino","sequence":"additional","affiliation":[{"name":"IBD Center Department of Gastroenterology IRCCS Humanitas Research Hospital Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Del Giovane","sequence":"additional","affiliation":[{"name":"Department of Diagnostics, Clinical and Public Health Medicine University of Modena and Reggio Emilia Modena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bonovas","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences for Health University of Milan Milan Italy"},{"name":"Laboratory of Drug Regulatory Policies IRCCS Mario Negri Institute for Pharmacological Research Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,4,13]]},"reference":[{"key":"e_1_2_7_2_1","volume-title":"Oxford Textbook of Medicine","author":"Jewell DP","year":"2005"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1932.02740680019005"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.01.055"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03536.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2009.12.002"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12749"},{"key":"e_1_2_7_8_1","unstructured":"FarrellRJ PeppercornMA.Overview of the medical management of mild to moderate Crohn's disease in adults. UpToDate website. Available at:http:\/\/www.uptodate.com\/contents\/overview-of-the-medical-management-of-mild-to-moderate-crohns-disease-in-adults?source=search_result&search=management+of+crohn%27s+disease&selectedTitle=1%7E150(accessed 27 March 2015)."},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f2914"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.331.7521.897"},{"key":"e_1_2_7_11_1","unstructured":"DaneseS FiorinoG DelGiovane C MojaL BonovasS.Comparative efficacy and safety of budesonide and mesalamine for Crohn's disease: a systematic review and network meta\u2010analysis of randomized controlled trials. PROSPERO 2014:CRD42014009300. Available at:http:\/\/www.crd.york.ac.uk\/PROSPERO\/display_record.asp?ID=CRD42014009300(accessed 27 March 2015)."},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00135"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(76)80163-1"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)92767-1"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008929526011"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.2307\/1390675"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.016"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.12.1269"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2012.06.006"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.71"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.11.004"},{"key":"e_1_2_7_23_1","first-page":"339","article-title":"Maintenance treatment with budesonide 6\u00a0mg versus 9\u00a0mg once daily in patients with Crohn's disease in remission","volume":"65","author":"Jong DJ","year":"2007","journal-title":"Neth J Med"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02338.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-003-0529-5"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1053\/cgh.2003.50015"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05835.x"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808063390603"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.42.4.493"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00285.x"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(97)70117-3"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.39.1.82"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1996.v110.pm8536887"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1995.tb00438.x"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199504000-00008"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199412000-00003"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409293311303"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(93)90337-C"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(93)90411-5"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(92)90822-G"},{"issue":"183","key":"e_1_2_7_41_1","first-page":"F44","article-title":"Mesalazine (Pentasa) as prophylaxis in Crohn's disease. A multicenter, controlled trial","volume":"26","author":"Bondesen S","year":"1991","journal-title":"Scand J Gastroenterol"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1990.tb00449.x"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365528708991929"},{"key":"e_1_2_7_44_1","unstructured":"A study with pentasa in patients with active crohn's disease (PEACE). Available at:http:\/\/clinicaltrials.gov\/show\/NCT00862121(accessed 27 March 2015)"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.00212.x"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1996.v110.pm8608877"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1159\/000200228"},{"key":"e_1_2_7_48_1","first-page":"133","article-title":"Long\u2010term therapy with 5\u2010aminosalicylic acid in Crohn's disease: is it useful? Our four years experience","volume":"14","author":"Bresci G","year":"1994","journal-title":"Int J Clin Pharmacol Res"},{"key":"e_1_2_7_49_1","first-page":"71A","article-title":"New oral preparations for maintenance therapy in Crohn's disease","volume":"2","author":"Wellmann W","year":"1988","journal-title":"Can J Gastroenterol"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01308338"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.48.2.186"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1159\/000199279"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.70"},{"key":"e_1_2_7_54_1","first-page":"CD000296","article-title":"Budesonide for induction of remission in Crohn's disease","author":"Seow CH","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_55_1","first-page":"CD002913","article-title":"Budesonide for maintenance of remission in Crohn's disease","volume":"8","author":"Kuenzig ME","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_56_1","first-page":"CD008870","article-title":"Aminosalicylates for induction of remission or response in Crohn's disease","author":"Lim WC","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_57_1","first-page":"CD003715","article-title":"Oral 5\u2010aminosalicylic acid for maintenance of medically\u2010induced remission in Crohn's Disease","author":"Akobeng AK","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0010035"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-2-201307160-00008"},{"key":"e_1_2_7_60_1","volume-title":"Indirect Evidence: Indirect Treatment Comparisons in Meta\u2010analysis","author":"Wells G","year":"2009"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1159\/000353806"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12929"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.13190","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.13190","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T07:05:11Z","timestamp":1695539111000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.13190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,13]]},"references-count":61,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1111\/apt.13190"],"URL":"https:\/\/doi.org\/10.1111\/apt.13190","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,13]]}}}